Status:
RECRUITING
The Association Between Non-vitamin K Antagonist Oral Anticoagulant Therapy and Acute Stroke Severity and Post Stroke Short-term and Long-term Outcomes.
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Therapeutic Drug Monitoring
Eligibility:
All Genders
20+ years
Brief Summary
Non-vitamin K antagonist oral anticoagulant (NOAC) is the first line therapy to prevent thromboembolism in atrial fibrillation (AF) patients. Previous investigation showed that preceding NOAC therapy ...
Eligibility Criteria
Inclusion
- Atrial fibrillation
- Under dabigatran, rivaroxaban, apixaban or edoxaban therapy.
- Developing ischemic stroke, transient ischemic attack or intracranial hemorrhage during NOAC therapy.
Exclusion
- Refuse to provide blood sample for non-vitamin K antagonist oral anticoagulant (NOAC) concentration measurement.
- Refuse to provide informed consent.
Key Trial Info
Start Date :
February 25 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05283174
Start Date
February 25 2022
End Date
December 31 2027
Last Update
March 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100